Clinical Trial Update: A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating different dosing schedules of selumetinib in combination with cisplatin and gemcitabine versus cisplatin/gemcitabine alone for biliar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Carcinoma
• Gallbladder Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Selumetinib (selumetinib)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Biliary Tract Carcinoma, Gallbladder Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING